Market Movers: Oriel Morrison interviews Jennifer Chow, MD and CEO of Chimeric Therapeutics (ASX:CHM)

Link copied to
clipboard

Stockhead’s Market Movers video series features one-on-one interviews showcasing the major announcements of emerging ASX companies.

In this instalment, former CNBC, Sky News, and Bloomberg news anchor Oriel Morrison interviews Jennifer Chow, managing director and CEO of Chimeric Therapeutics (ASX:CHM).

Chimeric Therapeutics is the only clinical stage, cell therapy biotechnology company in Australia. The company’s focus is on discovering, developing and commercialising novel cell therapies with the most curative potential for patients.

To hear more, click above.  

share

• 
• 
• 
• 

Link copied to
clipboard

SUBSCRIBE

Get the latest Stockhead news delivered free to your inbox.

Name*

Email*

This field is hidden when viewing the form

Email Lists

Morning Update

Lunch Update

Market Close Update

Weekend Update

Spotlight

Comments

This field is for validation purposes and should be left unchanged.

It's free. Unsubscribe whenever you want.

By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.

You might be interested in

On the Bid

CAR-T therapies are leading the race to cure cancer

September 27, 2022 | Oriel Morrison

Break It Down

Break it Down: Radiopharm Theranostics progresses along path to help heal HER-2 cancer

December 20, 2024 | Stockhead TV

Health & Biotech

FDA pre-approval inspection of EBR’s WiSE CRT system set for early January

December 20, 2024 | Special Report